Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 4Venous Thromboembolism 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Hematologic Neoplasms 1Cytochrome P450 Interaction 1Advanced Solid Tumor 1ALK-positive Advanced Tumors 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × Warfarin × Clear all
NCT01388335 2020-07-01

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

Eli Lilly and Company

Phase 1 Completed
13 enrolled 17 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡